Affinity Asset Advisors LLC Acquires 130,312 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Affinity Asset Advisors LLC boosted its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,095,924 shares of the company's stock after purchasing an additional 130,312 shares during the quarter. Centessa Pharmaceuticals comprises about 2.5% of Affinity Asset Advisors LLC's investment portfolio, making the stock its 12th largest position. Affinity Asset Advisors LLC owned about 0.83% of Centessa Pharmaceuticals worth $18,357,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after acquiring an additional 865 shares in the last quarter. Barclays PLC grew its holdings in Centessa Pharmaceuticals by 1,414.9% in the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock valued at $89,000 after purchasing an additional 4,952 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after purchasing an additional 5,316 shares during the period. XTX Topco Ltd increased its stake in Centessa Pharmaceuticals by 122.9% during the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after buying an additional 12,506 shares in the last quarter. Finally, State Street Corp acquired a new position in Centessa Pharmaceuticals in the 3rd quarter valued at $777,000. 82.01% of the stock is owned by institutional investors.

Insider Transactions at Centessa Pharmaceuticals

In other news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the transaction, the chief executive officer now owns 429,398 shares of the company's stock, valued at approximately $6,771,606.46. This trade represents a 11.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Tia L. Bush sold 11,000 shares of the business's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $185,460.00. Following the completion of the sale, the chief technology officer now directly owns 121,503 shares of the company's stock, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 254,168 shares of company stock worth $4,217,828. 11.59% of the stock is currently owned by company insiders.

Centessa Pharmaceuticals Price Performance

Shares of CNTA stock traded up $0.47 during midday trading on Friday, reaching $12.30. 784,645 shares of the company traded hands, compared to its average volume of 608,764. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The firm has a market cap of $1.64 billion, a PE ratio of -8.04 and a beta of 1.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm's 50 day simple moving average is $14.84 and its two-hundred day simple moving average is $15.97.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CNTA shares. Guggenheim restated a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Morgan Stanley reaffirmed an "overweight" rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Piper Sandler began coverage on Centessa Pharmaceuticals in a research report on Monday, March 31st. They set an "overweight" rating and a $38.00 price objective for the company. Finally, TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.